Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42

Benzinga Newsdesk www.benzinga.com Neutral 72.5%

Neg 0% Neu 72.5% Pos 0%

Piper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Overweight rating and announces Price Target of $42.